Safety Profile of Durvalumab in Locally Advanced NSCLC

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=5Ej-Jn4yVMw

Julie Brahmer, MD, evaluates the safety profile of durvalumab as a systemic treatment, after chemotherapy plus concurrent radiation therapy, for locally advanced non–small cell lung cancer. • For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/

#############################

New on site